Second-Generation Jak2 Inhibitors for Advanced Prostate Cancer: Are We Ready for Clinical Development?

SIMPLE SUMMARY: Prostate Cancer (PC) is currently estimated to affect 1 in 9 men and is the second leading cause of cancer in men in the US. While androgen deprivation therapy, which targets the androgen receptor, is one of the front-line therapies for advanced PC and for recurrence of organ-confine...

Descripción completa

Detalles Bibliográficos
Autores principales: Beinhoff, Paul, Sabharwal, Lavannya, Udhane, Vindhya, Maranto, Cristina, LaViolette, Peter S., Jacobsohn, Kenneth M., Tsai, Susan, Iczkowski, Kenneth A., Wang, Liang, Hall, William A., Dehm, Scott M., Kilari, Deepak, Nevalainen, Marja T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533841/
https://www.ncbi.nlm.nih.gov/pubmed/34680353
http://dx.doi.org/10.3390/cancers13205204

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533841/
https://www.ncbi.nlm.nih.gov/pubmed/34680353
http://dx.doi.org/10.3390/cancers13205204

Ejemplares similares